Clinical Trial Update: Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating JDQ443 as a single-agent first-line therapy for locally advanced or metastatic KRAS G12C-mutated non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JDQ443 (JDQ443)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-09